Boserolimab

Boserolimab
Monoclonal antibody
Type	?
Clinical data
Other names	MK-5890
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2444297-08-7;
UNII	576SCZ7V2P;

Boserolimab (MK-5890) is a monoclonal antibody in development for lung cancer. It is developed by Merck.^[1]^[2]^[3]

References[edit]

^ Peled, N.; Rodriguez-Abreu, D.; Bordoni, R.; Ellis, P.M.; Hochmair, M.; Müller, V.; Levchenko, E.; Zhou, H.; Zhao, B.; Lara-Guerra, H.; Ahn, M-J. (December 2021). "114TiP KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)". Annals of Oncology. 32: S1425. doi:10.1016/j.annonc.2021.10.132.
^ Guelen, Lars; Fischmann, Thierry O; Wong, Jerelyn; Mauze, Smita; Guadagnoli, Marco; Bąbała, Nikolina; Wagenaars, Jozef; Juan, Veronica; Rosen, David; Prosise, Winnie; Habraken, Maurice; Lodewijks, Imke; Gu, Danling; Stammen-Vogelzangs, Judith; Yu, Ying; Baker, Jeanne; Lutje Hulsik, David; Driessen-Engels, Lilian; Malashock, Dan; Kreijtz, Joost; Bertens, Astrid; de Vries, Evert; Bovens, Astrid; Bramer, Arne; Zhang, Yiwei; Wnek, Richard; Troth, Sean; Chartash, Elliot; Dobrenkov, Konstantin; Sadekova, Svetlana; van Elsas, Andrea; Cheung, Jason K; Fayadat-Dilman, Laurence; Borst, Jannie; Beebe, Amy M; Van Eenennaam, Hans (13 September 2022). "Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy". Journal for Immunotherapy of Cancer. 10 (9): e005049. doi:10.1136/jitc-2022-005049. ISSN 2051-1426. PMC 9472132. PMID 36100308.
^ Wickramarachchi, Dilki; Wagner, Julianne; Woo, Thomas; Ferrari, Federico; Steinmetz, Thomas; Helmy, Roy; Xu, Weifeng (25 January 2023). "A Novel Neutralization Antibody Assay Method to Overcome Drug Interference with Better Compatibility with Acid-Sensitive Neutralizing Antibodies". The AAPS Journal. 25 (1): 18. doi:10.1208/s12248-023-00783-9. PMID 36697923. S2CID 256267804.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Peled, N.; Rodriguez-Abreu, D.; Bordoni, R.; Ellis, P.M.; Hochmair, M.; Müller, V.; Levchenko, E.; Zhou, H.; Zhao, B.; Lara-Guerra, H.; Ahn, M-J. (December 2021). "114TiP KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)". Annals of Oncology. 32: S1425. doi:10.1016/j.annonc.2021.10.132.

[2] Guelen, Lars; Fischmann, Thierry O; Wong, Jerelyn; Mauze, Smita; Guadagnoli, Marco; Bąbała, Nikolina; Wagenaars, Jozef; Juan, Veronica; Rosen, David; Prosise, Winnie; Habraken, Maurice; Lodewijks, Imke; Gu, Danling; Stammen-Vogelzangs, Judith; Yu, Ying; Baker, Jeanne; Lutje Hulsik, David; Driessen-Engels, Lilian; Malashock, Dan; Kreijtz, Joost; Bertens, Astrid; de Vries, Evert; Bovens, Astrid; Bramer, Arne; Zhang, Yiwei; Wnek, Richard; Troth, Sean; Chartash, Elliot; Dobrenkov, Konstantin; Sadekova, Svetlana; van Elsas, Andrea; Cheung, Jason K; Fayadat-Dilman, Laurence; Borst, Jannie; Beebe, Amy M; Van Eenennaam, Hans (13 September 2022). "Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy". Journal for Immunotherapy of Cancer. 10 (9): e005049. doi:10.1136/jitc-2022-005049. ISSN 2051-1426. PMC 9472132. PMID 36100308.

[3] Wickramarachchi, Dilki; Wagner, Julianne; Woo, Thomas; Ferrari, Federico; Steinmetz, Thomas; Helmy, Roy; Xu, Weifeng (25 January 2023). "A Novel Neutralization Antibody Assay Method to Overcome Drug Interference with Better Compatibility with Acid-Sensitive Neutralizing Antibodies". The AAPS Journal. 25 (1): 18. doi:10.1208/s12248-023-00783-9. PMID 36697923. S2CID 256267804.

[1]

[2]

[3]